FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016304477> ?p ?o ?g. }

• W2016304477 abstract "Introduction: For treatment of castration-refractory prostate cancer (CRPC) patients a systemic chemotherapy and a second line hormone therapy have been developed in the last years. The administration of the chemotherapeutic drug docetaxel in combination with prednisone given to patients with CRPC on the basis of its improved survival, pain reduction, PSA response, and quality of life is the state of the art treatment at the moment. However, many patients do not respond to docetaxel or develop a resistance during treatment. Due to the low overall response survival of the patient is prolonged just for a few months. Until now, not much of molecular characteristics for docetaxel resistance is known in prostate cancer. Therefore, the main aim of the study was the establishment and characterization of docetaxel resistant cell lines. For this reason we generated docetaxel resistent sub cell lines of DU-145 and PC3 cells, which are considered models for an advanced disease. Methods: PC3 and DU-145 cells were treated with increasing concentrations of docetaxel (up to 12,5nM). The resistance of the newly established sub lines was determined by testing cell viability, proliferation, apoptosis, and cell cycle regulation with MTT, [3H]thymidine incorporation assay and FACS measurement, respectively. Results: Treatment of parental PC3 and DU-145 cells with 12,5nM docetaxel up to 4 days leads to a significant decrease in cell viability. An increase of cleaved PARP protein after 48h for DU-145 and after 72h for PC3 cells could confirm this observation. In contrast to parental cells, the newly established PC3-DR and DU-145-DR docetaxel resistant cells have a different cell morphology. Treatment with docetaxel did not result in increased cPARP levels. Moreover, we could not detect a significant difference in proliferation, basal apoptosis and cell cycle regulation in a direct comparison between parental PC3 and PC3-DR cells. DU-145-DR cells showed a slight increase in apoptosis and a significant decrease in proliferation after docetaxel treatment. However, we still observed a higher viability compared to parental DU-145 cells treated with 12.5nM docetaxel. Conclusions: The generated sub lines are less sensitive to docetaxel compared to the parental cells. However, DU-145-DR cells are more sensitive to docetaxel than PC3-DR cells. Taken together, we report on successful establishment and characterization of docetaxel-resistant PC3 and DU-145 cells. These cells represent a promising cellular model to investigate the responsible molecular mechanism for docetaxel resistance in prostate cancer cells in vitro. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1711. doi:10.1158/1538-7445.AM2011-1711" @default.
• W2016304477 created "2016-06-24" @default.
• W2016304477 creator A5006782095 @default.
• W2016304477 creator A5007312106 @default.
• W2016304477 creator A5009151684 @default.
• W2016304477 creator A5054322548 @default.
• W2016304477 creator A5064487157 @default.
• W2016304477 creator A5082650526 @default.
• W2016304477 date "2011-04-15" @default.
• W2016304477 modified "2023-09-26" @default.
• W2016304477 title "Abstract 1711: Establishment and characterization of docetaxel resistant prostate cancer cell lines" @default.
• W2016304477 doi "https://doi.org/10.1158/1538-7445.am2011-1711" @default.
• W2016304477 hasPublicationYear "2011" @default.
• W2016304477 type Work @default.
• W2016304477 sameAs 2016304477 @default.
• W2016304477 citedByCount "0" @default.
• W2016304477 crossrefType "proceedings-article" @default.
• W2016304477 hasAuthorship W2016304477A5006782095 @default.
• W2016304477 hasAuthorship W2016304477A5007312106 @default.
• W2016304477 hasAuthorship W2016304477A5009151684 @default.
• W2016304477 hasAuthorship W2016304477A5054322548 @default.
• W2016304477 hasAuthorship W2016304477A5064487157 @default.
• W2016304477 hasAuthorship W2016304477A5082650526 @default.
• W2016304477 hasConcept C121608353 @default.
• W2016304477 hasConcept C126322002 @default.
• W2016304477 hasConcept C143998085 @default.
• W2016304477 hasConcept C185592680 @default.
• W2016304477 hasConcept C190283241 @default.
• W2016304477 hasConcept C2776694085 @default.
• W2016304477 hasConcept C2780192828 @default.
• W2016304477 hasConcept C2781190966 @default.
• W2016304477 hasConcept C502942594 @default.
• W2016304477 hasConcept C53227056 @default.
• W2016304477 hasConcept C55493867 @default.
• W2016304477 hasConcept C71924100 @default.
• W2016304477 hasConcept C96232424 @default.
• W2016304477 hasConcept C98274493 @default.
• W2016304477 hasConceptScore W2016304477C121608353 @default.
• W2016304477 hasConceptScore W2016304477C126322002 @default.
• W2016304477 hasConceptScore W2016304477C143998085 @default.
• W2016304477 hasConceptScore W2016304477C185592680 @default.
• W2016304477 hasConceptScore W2016304477C190283241 @default.
• W2016304477 hasConceptScore W2016304477C2776694085 @default.
• W2016304477 hasConceptScore W2016304477C2780192828 @default.
• W2016304477 hasConceptScore W2016304477C2781190966 @default.
• W2016304477 hasConceptScore W2016304477C502942594 @default.
• W2016304477 hasConceptScore W2016304477C53227056 @default.
• W2016304477 hasConceptScore W2016304477C55493867 @default.
• W2016304477 hasConceptScore W2016304477C71924100 @default.
• W2016304477 hasConceptScore W2016304477C96232424 @default.
• W2016304477 hasConceptScore W2016304477C98274493 @default.
• W2016304477 hasLocation W20163044771 @default.
• W2016304477 hasOpenAccess W2016304477 @default.
• W2016304477 hasPrimaryLocation W20163044771 @default.
• W2016304477 hasRelatedWork W1969135551 @default.
• W2016304477 hasRelatedWork W1980559474 @default.
• W2016304477 hasRelatedWork W2022292123 @default.
• W2016304477 hasRelatedWork W2030068900 @default.
• W2016304477 hasRelatedWork W2036273299 @default.
• W2016304477 hasRelatedWork W2050676070 @default.
• W2016304477 hasRelatedWork W2059944478 @default.
• W2016304477 hasRelatedWork W2072845911 @default.
• W2016304477 hasRelatedWork W2073221931 @default.
• W2016304477 hasRelatedWork W2086661558 @default.
• W2016304477 hasRelatedWork W2140356862 @default.
• W2016304477 hasRelatedWork W2333550485 @default.
• W2016304477 hasRelatedWork W2336747239 @default.
• W2016304477 hasRelatedWork W2351692996 @default.
• W2016304477 hasRelatedWork W2382307896 @default.
• W2016304477 hasRelatedWork W2611791473 @default.
• W2016304477 hasRelatedWork W3005755617 @default.
• W2016304477 hasRelatedWork W3082058505 @default.
• W2016304477 hasRelatedWork W3186610503 @default.
• W2016304477 hasRelatedWork W45870531 @default.
• W2016304477 isParatext "false" @default.
• W2016304477 isRetracted "false" @default.
• W2016304477 magId "2016304477" @default.
• W2016304477 workType "article" @default.